Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 4, 2022– Initial Clinical Activity Results of IMU-935 in Psoriasis Expected in the Fourth Quarter – – Unblinded Safety Data from…Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
August 2, 2022NEW YORK, August 2, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update
July 28, 2022– Webcast to be Held at 8:00 am ET on August 4, 2022 – NEW YORK, July 28, 2022 – Immunic,…Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén
July 6, 2022– Global Commercial Executive Brings 20 Years of Sales and Marketing Expertise – – Jan Van den Bossche Steps Down from Board After…Immunic to Participate in Industry and Scientific Conferences in July
June 28, 2022NEW YORK, June 28, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology
June 15, 2022NEW YORK, June 15, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June
June 8, 2022NEW YORK, June 8, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update
June 2, 2022– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and…Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022– Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis Expected Next Month – –…Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease
May 5, 2022– First Time Patients Will be Treated with the Company’s Orally Available Small Molecule Modulator Targeting Restoration of Intestinal Barrier…